[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635422":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":99,"collaborators":101,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":11,"eligibilityCriteria":114,"healthyVolunteers":111,"sex":115,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":11,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":133,"whyStopped":11,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Goserelin group","EXPERIMENTAL",null,[13],"Drug: Goserelin",{"label":15,"type":16,"description":11,"interventionNames":11},"Control group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Goserelin","Subcutaneous injection of 3.6 mg of goserelin acetate once, administered 1 to 3 days prior to allogeneic haematopoietic stem cell transplantation.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"wei Shi","CONTACT","86-13207131315","496020121@qq.com",[30,48,63,69,84],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450000","China","CN",{"type":38,"coordinates":39},"Point",[40,41],113.64861,34.75778,{"lat":41,"lon":40},[44],{"name":45,"role":26,"phone":46,"phoneExt":11,"email":47},"jie wei Cao","86-15093360671","15093360671@163.com",{"facility":49,"status":11,"city":50,"state":51,"zip":52,"country":35,"countryCode":36,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei","430000",{"type":38,"coordinates":54},[55,56],114.26667,30.58333,{"lat":56,"lon":55},[59],{"name":60,"role":26,"phone":61,"phoneExt":11,"email":62},"yang Cao","86-13986142606","13986142606@163.com",{"facility":5,"status":11,"city":50,"state":51,"zip":52,"country":35,"countryCode":36,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},{"type":38,"coordinates":65},[55,56],{"lat":56,"lon":55},[68],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"facility":70,"status":11,"city":71,"state":72,"zip":73,"country":35,"countryCode":36,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"The First People's Hospital of Yunnan Province","Kunming","Yunnan","650000",{"type":38,"coordinates":75},[76,77],102.71833,25.03889,{"lat":77,"lon":76},[80],{"name":81,"role":26,"phone":82,"phoneExt":11,"email":83},"jie ya Wang","86-13211630338","13211630338@163.com",{"facility":85,"status":11,"city":86,"state":87,"zip":88,"country":35,"countryCode":36,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000",{"type":38,"coordinates":90},[91,92],120.16142,30.29365,{"lat":92,"lon":91},[95],{"name":96,"role":26,"phone":97,"phoneExt":11,"email":98},"min yan Zhao","86-15858199217","15858199217@163.com",{"type":100,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[102,104,105,107],{"name":103,"class":6},"Wuhan TongJi Hospital",{"name":31,"class":6},{"name":106,"class":6},"First Affiliated Hospital of Zhejiang University",{"name":108,"class":6},"The First People's Hospital of Yunnan","100635422","clinical-study-on-the-preservation-of-ovarian-function-following-hematopoietic-stem-cell-transplantation-in-patients-with-malignant-hematologic-diseases-using-goserelin-100635422",false,"NCT07552480","Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin","Inclusion Criteria:\n\n1\\. Patients with malignant hematologic disorders scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT); 2. Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; 3. Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating ability to understand and comply with all study procedures and requirements; 4. Expected survival exceeding 1 year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n1\\. Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may affect study outcomes or increase patient risk; 2. Patients with a history of allergy to goserelin or other related medications; 3. Patients who have already undergone menopause due to physiological or pathological factors; 4. Patients with a history of gynecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; 5. Patients currently participating in other clinical studies that may affect menstrual recovery; 6. Patients who refuse to participate in this clinical study.","FEMALE","14 Years","50 Years",{"count":119,"type":120},64,"ESTIMATED","INTERVENTIONAL",[123],"NA","This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female patients with malignant hematologic diseases aged 14-50 years who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group. The non-MAC group refers to a primary conditioning regimen where the main conditioning agents-busulfan (Bu) ≤ 6.4 mg\u002Fkg, melphalan (Mel) ≤ 140 mg\u002Fm², and thiotepa ≤ 10 mg\u002Fkg-are combined. Patients receiving this primary chemotherapy regimen will be assigned to the MAC group. Within each group (MAC or non-MAC), patients were randomly assigned 1:1 to either the experimental group (goserelin prophylaxis) or the control group using a random number table. The experimental group received a single 3.6 mg subcutaneous injection of goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group did not receive goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplantation. Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; other reproductive indicators: ovarian volume, endometrial thickness; Neutrophil\u002Fplatelet engraftment time; Complications: incidence of acute\u002Fchronic graft-versus-host disease (aGVHD\u002FcGVHD), EBV\u002FCMV infection rates; Disease recurrence rate; Transplant-related mortality; Adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in improving ovarian function following hematopoietic stem cell transplantation in patients with malignant hematologic diseases.",[126,127,128],"Allogeneic Haematopoietic Stem Cell Transplantation","Malignant Hematologic Disease","Ovarian Insufficiency",[130,131,132],"Malignant Hematologic Diseases","Allogeneic haematopoietic stem cell transplantation","Ovarian insufficiency","NOT_YET_RECRUITING","2026-04-20",{"date":136,"type":137},"2026-04-27","ACTUAL",{"date":139,"type":120},"2026-05-01",{"date":141,"type":120},"2027-10-01",{"name":5,"class":6},5]